ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Data Note
Revised

Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation

[version 3; peer review: 1 approved, 2 approved with reservations]
Previously titled: The identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation
PUBLISHED 29 Sep 2023
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the YCharOS (Antibody Characterization through Open Science) gateway.

This article is included in the Cell & Molecular Biology gateway.

Abstract

Apolipoprotein E is a secreted protein involved in mediating lipid distribution and metabolism among cells of specific tissues. The dysregulation of Apolipoprotein E can disturb cholesterol homeostasis, resulting in several diseases, including cardiovascular disease and Alzheimer’s disease. The therapeutic potential of Apolipoprotein E against these diseases demonstrates the importance of providing high-quality antibodies for this protein to the scientific community. In this study, we characterized fourteen Apolipoprotein E commercial antibodies for Western Blot and immunoprecipitation, using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. We identified many high-performing antibodies and encourage readers to use this report as a guide to select the most appropriate antibody for their specific needs.

Keywords

Uniprot ID P02649, APOE, Apolipoprotein E, antibody characterization, antibody validation, Western Blot, immunoprecipitation

Revised Amendments from Version 2

In this new version, Figure 1 has been updated to repeat Western blot testing for antibodies ab1907* and MA5-15852* to determine whether they would successfully target ApoE when using a dilution of 1/200 rather than 1/1000. Table 1 was also updated. The title was also amended.

See the authors' detailed response to the review by Nathalie Macrez
See the authors' detailed response to the review by Leonard Kritharides and Maaike Kockx

Introduction

Apolipoprotein E, or APOE, is a 299 amino acid transcribed and secreted to regulate lipid homeostasis by controlling the uptake of cholesterol and lipoproteins via receptor-mediated endocytosis.1,2 Three major isoforms of APOE exist, apoE4, apoE3, and apoE2.1 Despite only differing by single amino acid substitutions, their functionalities are altered at both the cellular and molecular levels.1 Accordingly, the binding affinity of APOE to its ligand, the LDL receptor (LDLR), varies depending on the isoform.2 ApoE3 and apoE4 bind to LDLR with high affinity while apoE2 binds with low affinity.3

Association studies have demonstrated apoE4 to be a genetic risk factor for cardiovascular disease, as it can cause high levels of circulating cholesterol, in the form of LDL as well as a genetic risk factor for late-onset Alzheimer’s disease.47 The critical role of APOE in health and disease highlights the need for additional research into the protein’s mechanism of action and potential for therapeutic strategies.8 Mechanistic studies would be greatly facilitated with the availability of validated and high-quality antibodies.

Here, we compared the performance of a range of commercially-available antibodies for Apolipoprotein E and validated several antibodies for Western Blot and immunoprecipitation, enabling biochemical and cellular assessment of Apolipoprotein E properties and function.

Results and discussion

Our standard protocol involves comparing readouts from wild-type (WT) and knockout (KO) cells.911 The first step was to identify a cell line(s) that expresses sufficient levels of Apolipoprotein E to generate a measurable signal. To this end, we examined the DepMap transcriptomics database to identify all cell lines that express the target at levels greater than 2.5 log2 (transcripts per million “TPM” + 1), which we have found to be a suitable cut-off (Cancer Dependency Map Portal, RRID:SCR_017655). Commercially available HAP1 cells expressed the APOE transcript at RNA levels above the average range of cancer cells analyzed. Parental and APOE knockout HAP1 cells were obtained from Horizon Discovery (Table 1).

Table 1. Summary of the cell lines used.

InstitutionCatalog numberRRID (Cellosaurus)Cell lineGenotype
Horizon DiscoveryC631CVCL_Y019HAP1WT
Horizon DiscoveryHZGHC005366c001CVCL_SC97HAP1APOE KO (16bp deletion)

Apolipoprotein E is predicted to be a secreted protein. Accordingly, we collected concentrated culture media from both WT and APOE KO cells and used the conditioned media to probe the performance of the antibodies (Table 2) side-by-side by Western Blot and immunoprecipitation.10,11 The profiles of the tested antibodies are shown in Figures 1 and 2.

Table 2. Summary of the Apolipoprotein E antibodies tested.

CompanyCatalog numberLot numberRRID (Antibody Registry)ClonalityImmunogenic regionClone IDHostConcentration (μg/μL)Vendors recommended applications
GeneTexGTX635889*44195AB_2909916monoclonalproprietary informationGT27711mouse1.0Wb
GeneTexGTX635891*44195AB_2909917monoclonalproprietary informationGT1627mouse1.0Wb
Abcamab52607**GR33789797AB_867704recombinant-monoproprietary informationEP1374Yrabbit0.1Wb, IP, IF
Abcamab51015**GR19880919AB_867703recombinant-monoproprietary informationEP1373Yrabbit0.14Wb, IP, IF
Abcamab1907*GR33619625AB_302669monoclonalpolymorphic amino acid 158E6D7mouse1.0IF
Cell Signaling Technology13366**4AB_2798191recombinant-monoproprietary informationD7I9Nrabbitn/aWb, IP, IF
Aviva Systems BiologyARP54283QC56479-160608AB_10640958polyclonalN-terminal -rabbit0.5Wb
Thermo Fisher Scientific701241**2477346AB_2532438recombinant-monoamino acids 240-25116H22L18rabbit0.5Wb, IF
Thermo Fisher ScientificMA5-41148**XH3670137AB_2898902recombinant-monoC-terminal SC0536rabbit1.0Wb
Thermo Fisher ScientificMA5-15852*XH3669852AB_11153583monoclonalrecombinant fragment1H4mousen/aWb
Bio-TechneMAB41441*ZRQ0318021AB_2289763monoclonalrecombinant fragment395004rat5.0Wb
Bio-TechneNB110-60531*COEN01-2AB_920623monoclonalproprietary informationnWUE-4mouse1.0Wb, IP
Proteintech18254-1-AP68183AB_2878525polyclonalfusion protein Ag13070rabbit0.4Wb
Proteintech66830-1-Ig*10008911AB_2882173monoclonalfusion protein Ag281861B2C9mouse2.1Wb, IF

* Monoclonal antibody.

** Recombinant antibody.

77aecbc1-800e-4365-82bd-97ccdc978044_figure1.gif

Figure 1. Apolipoprotein E antibody screening by Western Blot on culture media.

HAP1 WT and APOE KO were cultured in serum free media. Media were collected, concentrated, and 30 μg of protein were processed for Western Blot with the indicated Apolipoprotein E antibodies. The Ponceau stained transfers of each blot are shown. Antibody dilutions were chosen according to the recommendations of the antibody supplier. Exceptions were given for antibodies ab1907*,13366**,18254-1-AP, MA5-15852* and 66830-1-Ig* which were titrated to the concentrations listed below, as the signals were too weak when following the supplier’s recommendations. Antibody dilutions used: GTX635889* at 1/200, GTX635891* at 1/200, ab52607** at 1/200, ab51015** at 1/1000, ab1907* at 1/200, 13366** at 1/500, ARP54283 at 1/1000, 701241** at 1/200, MA5-41148** at 1/200, MA5-15852* at 1/200, MAB41441* at 1/200, NB110-60531* at 1/200, 18254-1-AP at 1/200, 66830-1-Ig* at 1/200. Apolipoprotein E predicted band size: 36 kDa. *Monoclonal antibody, **Recombinant antibody.

77aecbc1-800e-4365-82bd-97ccdc978044_figure2.gif

Figure 2. Apolipoprotein E antibody screening by immunoprecipitation on culture media.

Immunoprecipitation was performed on 0.9 mg concentrated culture media from HAP1 WT, and using 2.0 μg of the indicated Apolipoprotein E antibodies pre-coupled to protein G or protein A magnetic beads. Samples were washed and processed for Western Blot with the indicated Apolipoprotein E antibody. Antibody 13366** was used at 1/500 for all Western Blots. The Ponceau stained transfers of each blot are shown. SM=3% starting material; UB=3% unbound fraction; IP=immunoprecipitate; HC=heavy chain; *Monoclonal antibody, **Recombinant antibody.

In conclusion, we have screened Apolipoprotein E commercial antibodies by Western Blot and immunoprecipitation and identified several high-quality antibodies under our standardized experimental conditions. The underlying data was previously uploaded to an open access repository, Zenodo.12,13

Methods

Antibodies

All Apolipoprotein E antibodies are listed in Table 2, together with their corresponding Research Resource Identifiers (RRID), to ensure the antibodies are cited properly.14 All antibodies tested detect Human ApoE. Peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies are from Thermo Fisher Scientific (cat. number 65-6520 and 62-6120).

Cell culture

HAP1 WT and APOE KO cell lines used are listed in Table 1, together with their corresponding RRID, to ensure the cell lines are cited properly.15 Cells were cultured in DMEM high-glucose (GE Healthcare cat. number SH30081.01) containing 10% fetal bovine serum (Wisent, cat. number 080450), 2 mM L-glutamate (Wisent cat. number 609065), 100 IU penicillin and 100 μg/mL streptomycin (Wisent cat. number 450201). Cells were starved in DMEM high-glucose containing L-glutamate and penicillin/streptomycin.

Antibody screening by Western Blot on culture media

HAP1 cells WT and APOE KO were washed 3× with PBS 1× and starved for ~18 hrs. Culture media were collected and centrifuged for 10 min at 500× g to eliminate cells and larger contaminants, then for 10 min at 4500× g to eliminate smaller contaminants. Culture media were concentrated by centrifuging at 4000× g for 30 min using Amicon Ultra-15 Centrifugal Filter Units with a membrane NMWL of 10 kDa (MilliporeSigma cat. number UFC901024).

Western Blots were performed as described in our standard operating procedure.16 Midi precast 4-20% Tris-Glycine polyacrylamide gels from Thermo Fisher Scientific (cat. number WXP42012BOX) were used and proteins were transferred on nitrocellulose membranes. Proteins on the blots were visualized with Ponceau S staining (Thermo Fisher Scientific, cat. number BP103-10) which is scanned to show together with individual Western Blot. Blots were blocked with 5% milk for 1 hr, and antibodies were incubated overnight at 4°C with 5% bovine serum albumin (BSA) (Wisent, cat. number 800-095) in TBS with 0.1% Tween 20 (TBST) (Cell Signaling Technology, cat. number 9997). Following three washes with TBST, the peroxidase conjugated secondary antibody was incubated at a dilution of ~0.2 μg/mL in TBST with 5% milk for 1 hr at room temperature followed by three washes with TBST. Membranes were incubated with Pierce ECL from Thermo Fisher Scientific (cat. number 32106) or with Clarity Western ECL Substrate from Bio-Rad (cat. number 1705061) prior to detection with the iBright™ CL1500 Imaging System from Thermo Fisher Scientific (cat. number A44240).

Antibody screening by immunoprecipitation on culture media

Immunoprecipitation was performed as described in our standard operating procedure.17 Antibody-bead conjugates were prepared by adding 2 μg or 20 μL of antibody at an unknown concentration to 500 μL of Pierce IP Lysis Buffer from Thermo Fisher Scientific (cat. number 87788) in a 1.5 mL microcentrifuge tube, together with 30 μL of Dynabeads protein G - (for Mouse and rat antibodies) and protein A - (for rabbit antibodies) from Thermo Fisher Scientific (cat. number 10003D and 10002D, respectively). Pierce IP Lysis Buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol) was supplemented with the Halt Protease Inhibitor Cocktail 100X from Thermo Fisher Scientific (cat. number 78446) at a final concentration of 1×. Tubes were rocked for ~1 hr at 4°C followed by two washes to remove unbound antibodies. Starved HAP1 WT culture media were concentrated as described above. 0.6 mL aliquots at 1.5 mg/L of protein were incubated with an antibody-bead conjugate for ~1 hr at 4°C. The unbound fractions were collected, and beads were subsequently washed three times with 1.0 mL of IP Lysis Buffer and processed for SDS-PAGE and Western Blot on precast midi 4-20% Tris-Glycine polyacrylamide gels. Prot-A: HRP (MilliporeSigma, cat. number P8651) was used as a secondary detection system at a concentration 0.4 μg/mL.

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 11 Jul 2023
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Ayoubi R, Southern K, Laflamme C and NeuroSGC/YCharOS collaborative group. Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with reservations]. F1000Research 2023, 12:810 (https://doi.org/10.12688/f1000research.133899.3)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 3
VERSION 3
PUBLISHED 29 Sep 2023
Revised
Views
10
Cite
Reviewer Report 28 Dec 2023
Valerio Leoni, University of Milano-Bicocca, Desio, Italy 
Approved with Reservations
VIEWS 10
The manuscript Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation by Riham Ayoubi study the quality of commercial Anti-Apolipoporterin E antibodies.
The Apolipoprotein E is involved in lipid distribution and metabolism among cells, ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Leoni V. Reviewer Report For: Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with reservations]. F1000Research 2023, 12:810 (https://doi.org/10.5256/f1000research.156691.r228353)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 2
VERSION 2
PUBLISHED 26 Jul 2023
Revised
Views
16
Cite
Reviewer Report 18 Sep 2023
Nathalie Macrez, University Bordeaux, Bordeaux, France 
Approved with Reservations
VIEWS 16
The authors have compared commercially available apolipoprotein E antibodies for detection by Western blotting and immunoprecipitation using HAP1 cells expressing APOE and their KO counterparts lacking APOE. The resource is helpful but it lacks some information for full interpretation. It ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Macrez N. Reviewer Report For: Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with reservations]. F1000Research 2023, 12:810 (https://doi.org/10.5256/f1000research.153492.r201058)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 03 Oct 2023
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    03 Oct 2023
    Author Response
    Dear Nathalie Macrez,

    We’d first like to thank you for taking the time to generate an in-depth review of our antibody characterization study for Apolipoprotein E. Your feedback and ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 03 Oct 2023
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    03 Oct 2023
    Author Response
    Dear Nathalie Macrez,

    We’d first like to thank you for taking the time to generate an in-depth review of our antibody characterization study for Apolipoprotein E. Your feedback and ... Continue reading
Views
13
Cite
Reviewer Report 10 Aug 2023
Leonard Kritharides, Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia;  ANZAC Research Institute, The University of Sydney, Sydney, NSW, Australia 
Maaike Kockx, ANZAC Medical Research Institute, The University of Sydney, Sydney, NSW, Australia 
Approved
VIEWS 13
We are happy with the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Kritharides L and Kockx M. Reviewer Report For: Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with reservations]. F1000Research 2023, 12:810 (https://doi.org/10.5256/f1000research.153492.r190833)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 11 Jul 2023
Views
24
Cite
Reviewer Report 19 Jul 2023
Leonard Kritharides, Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia;  ANZAC Research Institute, The University of Sydney, Sydney, NSW, Australia 
Maaike Kockx, ANZAC Medical Research Institute, The University of Sydney, Sydney, NSW, Australia 
Approved with Reservations
VIEWS 24
The authors have compared and validated commercially available apolipoprotein E antibodies for detection by Western blotting and immunoprecipitation using HAP1 cells with and without apoE expression.The resource is helpful and could be improved by addressing the following:
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Kritharides L and Kockx M. Reviewer Report For: Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation [version 3; peer review: 1 approved, 2 approved with reservations]. F1000Research 2023, 12:810 (https://doi.org/10.5256/f1000research.146914.r186248)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 04 Aug 2023
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    04 Aug 2023
    Author Response
    Thank you to Leonard Kritharides and Maaike Kcokx for your extensive review of this article. We appreciate your constructive feedback and will be submitting a new version of the manuscript, ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 04 Aug 2023
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    04 Aug 2023
    Author Response
    Thank you to Leonard Kritharides and Maaike Kcokx for your extensive review of this article. We appreciate your constructive feedback and will be submitting a new version of the manuscript, ... Continue reading

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 11 Jul 2023
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.